parametric apparent diffusion coefficient maps (Kiromic LLC)
90
Structured Review
Kiromic LLC
parametric apparent diffusion coefficient maps
Parametric Apparent Diffusion Coefficient Maps, supplied by Kiromic LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apparent+diffusion+coefficient/parametric+apparent+diffusion+coefficient+maps/pm32002663-28-72-62
Average 90 stars, based on 1 article reviews
Parametric Apparent Diffusion Coefficient Maps, supplied by Kiromic LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apparent+diffusion+coefficient/parametric+apparent+diffusion+coefficient+maps/pm32002663-28-72-62
Average 90 stars, based on 1 article reviews
parametric apparent diffusion coefficient maps - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Diffusion-based Assay:Article Title: PD-L1, fibrosis, and immunotherapy in hepatocellular carcinoma: the importance of a scientific method to explore observations and answer questions. Article Snippet: In light of promising data demonstrating a restoration of host immunity against tumors after inhibition, the PD-1/PD-L1 axis has become a topic of particular interest.. Determining which patients derive benefit from PD-1/PD-L1-directed immunotherapy remains, however, an important clinical question, particularly in light of the reported broad spectrum of toxicity of these agents.. In a recent edition of Surgery Today, Elmezayen et al. [1] reported that PD-L1-expressing cells in the background liver, but not in the tumor tissue, appeared to contribute to the serum PD-L1 (sPDL1) level, suggesting that sPDL1 was not indicative of the tumor burden in patients with hepatocellular carcinoma (HCC). Activity Assay:Article Title: PD-L1, fibrosis, and immunotherapy in hepatocellular carcinoma: the importance of a scientific method to explore observations and answer questions. Article Snippet: In light of promising data demonstrating a restoration of host immunity against tumors after inhibition, the PD-1/PD-L1 axis has become a topic of particular interest.. Determining which patients derive benefit from PD-1/PD-L1-directed immunotherapy remains, however, an important clinical question, particularly in light of the reported broad spectrum of toxicity of these agents.. In a recent edition of Surgery Today, Elmezayen et al. [1] reported that PD-L1-expressing cells in the background liver, but not in the tumor tissue, appeared to contribute to the serum PD-L1 (sPDL1) level, suggesting that sPDL1 was not indicative of the tumor burden in patients with hepatocellular carcinoma (HCC). |
